David Forer

842 total citations
23 papers, 634 citations indexed

About

David Forer is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, David Forer has authored 23 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 13 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Cancer Research. Recurrent topics in David Forer's work include Prostate Cancer Treatment and Research (21 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Cancer Treatment and Pharmacology (6 papers). David Forer is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Cancer Treatment and Pharmacology (6 papers). David Forer collaborates with scholars based in United States, France and United Kingdom. David Forer's co-authors include Howard I. Scher, Mohammad Hirmand, Johann S. de Bono, Karim Fizazi, Cora N. Sternberg, Ethan Basch, David Cella, Kurt Miller, Andrew J. Armstrong and Tomasz M. Beer and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Cancer.

In The Last Decade

David Forer

23 papers receiving 624 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Forer United States	11	569	258	194	137	88	23	634
Giri Sulur United States	8	587 1.0×	216 0.8×	199 1.0×	159 1.2×	189 2.1×	19	796
Nahla Hasabou United States	9	245 0.4×	123 0.5×	88 0.5×	83 0.6×	67 0.8×	30	467
John Bernard France	5	363 0.6×	129 0.5×	135 0.7×	135 1.0×	29 0.3×	8	472
F. Gómez-Veiga Spain	14	707 1.2×	155 0.6×	196 1.0×	159 1.2×	106 1.2×	81	899
R. Nevin Murray Canada	7	540 0.9×	242 0.9×	173 0.9×	203 1.5×	80 0.9×	10	651
Francesca Vignani Italy	14	509 0.9×	163 0.6×	186 1.0×	263 1.9×	95 1.1×	46	750
Ines Figueiredo United Kingdom	11	356 0.6×	93 0.4×	232 1.2×	237 1.7×	90 1.0×	26	576
Spyridon Sideris Belgium	11	379 0.7×	189 0.7×	154 0.8×	158 1.2×	21 0.2×	27	504
Marie Hjälm-Eriksson Sweden	8	367 0.6×	83 0.3×	111 0.6×	113 0.8×	31 0.4×	17	455
Christoph A. von Klot Germany	13	477 0.8×	288 1.1×	110 0.6×	72 0.5×	34 0.4×	20	653

Countries citing papers authored by David Forer

Since Specialization

Citations

This map shows the geographic impact of David Forer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Forer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Forer more than expected).

Fields of papers citing papers by David Forer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Forer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Forer. The network helps show where David Forer may publish in the future.

Co-authorship network of co-authors of David Forer

This figure shows the co-authorship network connecting the top 25 collaborators of David Forer. A scholar is included among the top collaborators of David Forer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Forer. David Forer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alumkal, Joshi J., Simon Chowdhury, Yohann Loriot, et al.. (2017). Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clinical Genitourinary Cancer. 15(5). 610–617.e3. 24 indexed citations

Armstrong, Andrew J., Fred Saad, De Phung, et al.. (2017). Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel. Cancer. 123(12). 2303–2311. 31 indexed citations

Penson, David F., Daniel W. Lin, Lawrence I. Karsh, et al.. (2016). Treatment Registry for Outcomes in Patients with Castration-Resistant Prostate Cancer (TRUMPET): A Methodology for Real-World Evidence and Research. Future Oncology. 12(23). 2689–2699. 5 indexed citations

Armstrong, Andrew J., Fred Saad, Neal D. Shore, et al.. (2016). Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. Journal of Clinical Oncology. 34(15_suppl). 5062–5062. 1 indexed citations

Graff, Julie N., G. Baciarello, Andrew J. Armstrong, et al.. (2015). Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Annals of Oncology. 27(2). 286–294. 86 indexed citations

Higano, Celestia S., Tomasz M. Beer, Mary-Ellen Taplin, et al.. (2015). Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology. 68(5). 795–801. 40 indexed citations

Shore, Neal D., Axel Heidenreich, Arnauld Villers, et al.. (2015). PII-LBA4 TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. The Journal of Urology. 193(4S). 2 indexed citations

Graff, Julie N., Giulia Baciarello, Andrew J. Armstrong, et al.. (2015). Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.. Journal of Clinical Oncology. 33(7_suppl). 200–200. 3 indexed citations

Fizazi, Karim, Howard I. Scher, Kurt Miller, et al.. (2014). Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology. 15(10). 1147–1156. 151 indexed citations

10.

Sternberg, Cora N., Johann S. de Bono, K.N. Chi, et al.. (2014). Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of Oncology. 25(2). 429–434. 101 indexed citations

11.

Higano, Celestia S., Joshi J. Alumkal, S. Chowdhury, et al.. (2014). Response Rates and Outcomes with Enzalutamide for Patients with Metastatic Castration Resistant Prostate Cancer and Visceral Disease in the Prevail Trial. Annals of Oncology. 25. iv262–iv262. 5 indexed citations

12.

Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2013). Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. Journal of Clinical Oncology. 31(6_suppl). 6–6. 40 indexed citations

13.

Fleming, Mark T., Dana E. Rathkopf, Amy Peterson, et al.. (2013). Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer.. Journal of Clinical Oncology. 31(15_suppl). 5066–5066. 2 indexed citations

14.

Loriot, Yohann, Fred Saad, Johann S. de Bono, et al.. (2013). P109 Efficacy outcomes by baseline prostate-specific antigen (PSA): Results from the Phase III AFFIRM trial. European Urology Supplements. 12(6). 173–173. 2 indexed citations

15.

Fleming, Mark T., Howard I. Scher, Karim Fizazi, et al.. (2013). Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.. Journal of Clinical Oncology. 31(6_suppl). 20–20. 6 indexed citations

16.

Saad, Fred, Johann S. de Bono, Neal D. Shore, et al.. (2013). 785 EFFICACY OUTCOMES BY BASELINE PROSTATE-SPECIFIC ANTIGEN (PSA): RESULTS FROM THE PHASE 3 AFFIRM TRIAL. The Journal of Urology. 189(4S). 2 indexed citations

17.

Fleming, Mark T., Dana E. Rathkopf, Amy Peterson, et al.. (2013). Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.. Journal of Clinical Oncology. 31(6_suppl). 63–63. 9 indexed citations

18.

Loriot, Yohann, Karim Fizazi, Johann S. de Bono, et al.. (2013). Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.. Journal of Clinical Oncology. 31(15_suppl). 5065–5065. 14 indexed citations

19.

Miller, Mary K., David Forer, Elliot Israel, et al.. (2006). Enrollment Update of the Epidemiologic Study of Xolair: Evaluating the Long-Term Safety and Clinical Effectiveness in Patients with Moderate to Severe Asthma (EXCELS). Journal of Allergy and Clinical Immunology. 117(2). S12–S12. 2 indexed citations

20.

Kereiakes, Dean J., Dennis Wahr, Howard C. Herrmann, et al.. (2003). Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment. Circulation. 108(11). 1310–1315. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact